At 24/7 Wall St., we have closely followed dividend-paying stocks for over 15 years. With a growing audience of savvy Baby ...

The label update provides an option for patients who have received at least 1 approved systemic therapy if TNF blockers are clinically inadvisable.

The FDA has approved AbbVie’s supplemental new drug application for Rinvoq (upadacitinib) to treat inflammatory bowel disease ...

Updated indication allows the use of RINVOQ® (upadacitinib) prior to the use of tumor necrosis factor (TNF) blocking agents in patients for whom ...

AbbVie notched a huge win when it managed to extend patent exclusivity for a blockbuster drug. That drug, Rinvoq, drew in over $1.3 billion in sales last year. 10 stocks we like better than AbbVie › ...

COLFAX, Iowa — President Donald Trump said Sept. 25 that he would enact a 100% pharmaceutical tariff starting Oct. 1 for brand-name and patented pharmaceuticals. Products manufactured by companies who ...

AbbVie has a roughly 3% yield, limited patent cliff risk, and an aesthetic niche that has long legs. Coca-Cola has a roughly 3.1% yield, a well-run business, and an attractive valuation. Chevron has a ...

(SOUTH AMBOY, NJ) -- New Jersey internet radio station BlowUpRadio.com - Where NJ Rock Lives, announces its 18th annual Banding Together Webathon to benefit the Spondylitis Association Of America.

Combined, these five companies have returned over $500 billion to shareholders in the past decade while growing their dividends every single year. Yields range from Costco's modest 0.57% to Pfizer's ...

Several major advances in Crohn's disease have marked 2025, including two new FDA-approved therapies, emerging biologics that target novel pathways, and the first global standards for managing ...

Pharmaceutical stocks in Asia fell, but big pharma groups in Europe in the U.S. were largely unaffected after President Trump announced a 100% tariff on drugs by companies that aren’t building plants ...